StreetInsider.com News Articles

Medifast makes OPTAVIA eligible for HSA and FSA reimbursement

Fri, 20 Feb 2026 08:30:40 -0500

Medifast (NYSE: MED) announced that its OPTAVIA metabolic health system is now available for reimbursement on select insurance plans using Health Savings Accounts and Flexible Spending Accounts. The company stated that clients may save up to 40% on program costs by working with their medical provider and insurance administrator to use pre-tax medical funds.

The announcement comes as Medifast positions itself in the metabolic health market, citing research showing more than 90% of U.S. adults are classified as metabolically unhealthy. OPTAVIA combines what the company calls its "Metabolic Synchronization" approach with coaching services.

"This is a major moment for our company, and

Scientific Evidence Demonstrates OPTAVIA®’s Metabolic Health Benefits, Opening the Door to Qualified HSA/FSA Clients

Fri, 20 Feb 2026 08:30:00 -0500

BALTIMORE--(BUSINESS WIRE)-- As part of its continued focus on improving metabolic health, Medifast® (NYSE: MED) today announced that OPTAVIA’s comprehensive metabolic health system is available for reimbursement on select insurance plans using Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA). OPTAVIA clients may be able to save up to 40% on program costs by working with their medical provider and insurance administrator to use pre-tax medical funds, offering accessibility for those prioritizing their metabolic health.

This milestone reinforces Medifast’s position as a science-driven health and wellness leader, with a

Scientific Evidence Demonstrates OPTAVIA®’s Metabolic Health Benefits, Opening the Door to Qualified HSA/FSA Clients

Fri, 20 Feb 2026 08:30:00 -0500

This milestone reinforces Medifast’s position as a science-driven health and wellness leader, with a

Scientific Evidence Demonstrates OPTAVIA®’s Metabolic Health Benefits, Opening the Door to Qualified HSA/FSA Clients

Fri, 20 Feb 2026 08:30:00 -0500

This milestone reinforces Medifast’s position as a science-driven health and wellness leader, with a

Scientific Evidence Demonstrates OPTAVIA®’s Metabolic Health Benefits, Opening the Door to Qualified HSA/FSA Clients

Fri, 20 Feb 2026 08:30:00 -0500

This milestone reinforces Medifast’s position as a science-driven health and wellness leader, with a

Medifast (MED) PT Lowered to $12 at Stephens

Thu, 19 Feb 2026 07:47:15 -0500

(Updated - February 19, 2026 7:47 AM EST)

Stephens analyst Jim Salera lowered the price target on Medifast (NYSE: MED) to $12.00 (from $15.00) while maintaining a Equal Weight rating.

The analyst commented: "MED delivered 4Q25 revenue that was better than we expected, but the company continues to grapple with margin pressures from volume deleverage. The backdrop remains challenged as GLP-1 adoption and a value focused consumer weigh on client acquisition and category momentum. Into FY26, we believe the debate is centered on if improving coach productivity will yield a stabilization in total coach headcount. The hope would then be that an

Medifast (MED) PT Lowered to $12 at Stephens

Thu, 19 Feb 2026 07:47:15 -0500

(Updated - February 19, 2026 7:47 AM EST)

Stephens analyst Jim Salera lowered the price target on Medifast (NYSE: MED) to $12.00 (from $15.00) while maintaining a Equal Weight rating.

Form 10-K MEDIFAST INC For: Dec 31

Tue, 17 Feb 2026 16:54:00 -0500

si-local-file:///var/storage/secattach/20260217/26014643.html

Form 10-K MEDIFAST INC For: Dec 31

Tue, 17 Feb 2026 16:54:00 -0500

si-local-file:///var/storage/secattach/20260217/26014643.html

Form 8-K MEDIFAST INC For: Feb 17

Tue, 17 Feb 2026 16:45:00 -0500

si-local-file:///var/storage/secattach/20260217/26014391.html

Form 8-K MEDIFAST INC For: Feb 17

Tue, 17 Feb 2026 16:45:00 -0500

si-local-file:///var/storage/secattach/20260217/26014391.html

Medifast (MED) Misses Q4 EPS by 120c

Tue, 17 Feb 2026 16:05:39 -0500

Medifast (NYSE: MED) reported Q4 EPS of ($1.65), $1.20 worse than the analyst estimate of ($0.45). Revenue for the quarter came in at $75.1 million versus the consensus estimate of $73.8 million.

For earnings history and earnings-related data on Medifast (MED) click here.

Medifast Announces Fourth Quarter and Full Year 2025 Financial Results

Tue, 17 Feb 2026 16:05:00 -0500

BALTIMORE--(BUSINESS WIRE)-- Medifast (NYSE: MED), the health and wellness company known for its science-backed, coach-guided lifestyle system, today reported results for the fourth quarter and full year ended December 31, 2025.

Fourth Quarter 2025

Revenue of $75.1 million, with revenue per active earning coach of $4,664
Independent active earning coaches of 16,100
Net loss of $18.1 million, or $1.65 per diluted share ("EPS"), which includes the tax provision charge to establish a non-cash valuation allowance on the Company's deferred tax balance of $12.1 million (or $1.10 per diluted share)
Cash, cash equivalents, and investment Securities of $167.3

Medifast Announces Fourth Quarter and Full Year 2025 Financial Results

Tue, 17 Feb 2026 16:05:00 -0500

Fourth Quarter 2025

Revenue of $75.1 million, with revenue per active earning coach of $4,664
Independent active earning coaches of 16,100
Net loss of $18.1 million, or $1.65 per diluted share ("EPS"), which includes the tax provision charge to establish a non-cash valuation allowance on the Company's deferred tax balance of $12.1 million (or $1.10 per diluted share)
Cash, cash equivalents, and investment Securities of $167.3

Medifast Announces Fourth Quarter and Full Year 2025 Financial Results

Tue, 17 Feb 2026 16:05:00 -0500

Fourth Quarter 2025

Revenue of $75.1 million, with revenue per active earning coach of $4,664
Independent active earning coaches of 16,100
Net loss of $18.1 million, or $1.65 per diluted share ("EPS"), which includes the tax provision charge to establish a non-cash valuation allowance on the Company's deferred tax balance of $12.1 million (or $1.10 per diluted share)
Cash, cash equivalents, and investment Securities of $167.3

Medifast Announces Fourth Quarter and Full Year 2025 Financial Results

Tue, 17 Feb 2026 16:05:00 -0500

Fourth Quarter 2025

Revenue of $75.1 million, with revenue per active earning coach of $4,664
Independent active earning coaches of 16,100
Net loss of $18.1 million, or $1.65 per diluted share ("EPS"), which includes the tax provision charge to establish a non-cash valuation allowance on the Company's deferred tax balance of $12.1 million (or $1.10 per diluted share)
Cash, cash equivalents, and investment Securities of $167.3

Form SCHEDULE 13G/A MEDIFAST INC Filed by: SUSQUEHANNA SECURITIES, LLC

Fri, 13 Feb 2026 17:17:00 -0500

si-local-file:///var/storage/secattach/20260213/26002006.html

Form SCHEDULE 13G/A MEDIFAST INC Filed by: SUSQUEHANNA SECURITIES, LLC

Fri, 13 Feb 2026 17:17:00 -0500

si-local-file:///var/storage/secattach/20260213/26002006.html

Form SCHEDULE 13G/A MEDIFAST INC Filed by: CHARLES SCHWAB INVESTMENT MANAGEMENT INC

Thu, 12 Feb 2026 15:20:00 -0500

si-local-file:///var/storage/secattach/20260212/25991236.html

Form SCHEDULE 13G/A MEDIFAST INC Filed by: CHARLES SCHWAB INVESTMENT MANAGEMENT INC

Thu, 12 Feb 2026 15:20:00 -0500

si-local-file:///var/storage/secattach/20260212/25991236.html

Medifast to Announce Financial Results for the Fourth Quarter and Full Year Ended December 31, 2025

Tue, 03 Feb 2026 16:05:00 -0500

BALTIMORE--(BUSINESS WIRE)-- Medifast (NYSE: MED), the health and wellness company known for its science-backed, coach-guided lifestyle system, will announce financial results for the quarter and full year ended December 31, 2025 on Tuesday, February 17, 2026, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, Nick Johnson, President, and Jim Maloney, Chief Financial Officer.

The conference call is scheduled to begin at 4:30 p.m. ET on February 17, 2026. The call will be

Medifast to Announce Financial Results for the Fourth Quarter and Full Year Ended December 31, 2025

Tue, 03 Feb 2026 16:05:00 -0500

The conference call is scheduled to begin at 4:30 p.m. ET on February 17, 2026. The call will be

Medifast to Announce Financial Results for the Fourth Quarter and Full Year Ended December 31, 2025

Tue, 03 Feb 2026 16:05:00 -0500

The conference call is scheduled to begin at 4:30 p.m. ET on February 17, 2026. The call will be

Medifast to Announce Financial Results for the Fourth Quarter and Full Year Ended December 31, 2025

Tue, 03 Feb 2026 16:05:00 -0500

The conference call is scheduled to begin at 4:30 p.m. ET on February 17, 2026. The call will be

People Magazine Spotlights Tiffany Howard’s Metabolic Health Journey with OPTAVIA®

Fri, 16 Jan 2026 08:30:00 -0500

A Powerful Story of Improving Metabolic Health Through Science, Coaching and Community

BALTIMORE--(BUSINESS WIRE)-- Medifast® (NYSE: MED), the health and wellness company known for its science-backed, coach-guided lifestyle system OPTAVIA, celebrates the inspiring health transformation of Tiffany Howard, recently featured in People magazine. Tiffany’s journey highlights how OPTAVIA’s comprehensive program, which combines science-backed nutrition, personalized coaching and sustainable habit-building, reversed her metabolic dysfunction1. For Tiffany, this meant several meaningful health improvements, including healthy weight loss.

Before starting her OPTAVIA journey, Tiffany struggled with metabolic health challenges,